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EDITORIAL COMMENT
Another Nail in the
Coffin of Carotid Endarterectomy*
Christopher J. White, MD, FACC
New Orleans, Louisiana
The randomized carotid stent versus carotid surgery trial
reported by Brooks et al. (1) in this issue of the Journal is a
notable accomplishment in several respects. By reporting
results in 104 patients, it becomes the largest randomized
carotid artery stent versus carotid endarterectomy trial
published to date (to my knowledge). It is also an excellent
example of team building with a surgeon, a cardiologist and
a neurologist working together to optimize patient care. The
authors are to be congratulated on conducting a randomized
trial with prospective independent neurology oversight.
The trial, as do all clinical trials, has strengths and
weaknesses. The strengths include reasonably good meth-
odology with routine preprocedural and postprocedural
objective patient assessment by a neurologist and carotid
duplex ultrasound scans within 24 h of the procedure and
serially thereafter. Magnetic resonance imaging was per-
formed at 6 and 12 months after the procedure to detect
asymptomatic cerebrovascular ischemic events.
See page 1589
The major weakness of this trial is the relatively small
number of patients in each group which makes the extraor-
dinary low adverse event rates difficult to put in perspective.
The likelihood that a true difference between the two
treatments exists, and was not detected due to the small
sample size (beta error), is more likely than the authors
appear willing to admit. The low adverse event rates in both
surgery and stent groups may have been due to chance,
excellent operator skills or more likely a combination of
both.
The authors make an unconvincing attempt to quantify
hospital costs, length of stay and patient discomfort, which
do not appear to have been prespecified end points. We are
told there was little periprocedural discomfort in both
groups, which is not surprising. In the uncomplicated stent
patients, hospital stay was shorter compared to surgery, but
this was not true for patients who experienced complica-
tions. Specifically, excessive anticoagulation in each of the
three carotid stent patients receiving platelet glycoprotein
2b3a inhibitors resulted in retroperitoneal bleeding, pro-
longing their hospital stay. One carotid stent patient suf-
fered a lower extremity complication that required amputa-
tion and a prolonged (68 days) hospital stay. Five patients
underwent coronary artery surgery following carotid treat-
ment, but we are not told the distribution of these patients
between stent or surgery groups in order to appreciate their
impact on hospital stay. Clearly, if hospital stay were to be
a prespecified end point, then confounding variables, such as
a planned second procedure, would be distributed evenly
among the groups.
It is not clear from the article (1) how the cost and charge
data were applied to the procedures and the “variable costs”
were not specifically defined. In Table 5, for example, I
cannot tell where the cost of the predischarge carotid duplex
scan is allocated, or what algorithm was used to apportion
the nursing costs. When comparing stenting to surgery, the
increased cost of the disposable equipment (i.e., balloons
and stents) will need to be balanced against the shorter
hospital stay to determine the net cost reduction or increase.
Regardless, an early-phase randomized trial is not the best
way to assess treatment costs given that some procedures are
mandated by the protocol, and not necessarily by clinical
need.
Support for the parity in outcomes achieved in this study
comes from the recently published Carotid And Vertebral
Artery Transluminal Angioplasty Study (CAVATAS) mul-
ticenter trial, which randomized more than 500 patients
with symptomatic (96%) carotid artery stenoses to either
balloon angioplasty (bail-out stenting was allowed in 26%)
or surgery (2). The authors of CAVATAS acknowledged
that the results of balloon angioplasty would be out of date
when their study was published, as carotid stent placement
has emerged in the past few years as the preferred method.
CAVATAS demonstrated equal benefit for prevention of
stroke and death in both the surgery and angioplasty groups
at 30 days, which was sustained for 3 years, albeit at a higher
rate than previously reported. The 30-day incidence of any
stroke lasting more than 7 days or death was 10% in both
groups in the CAVATAS trial, substantially higher than in
the current report. The CAVATAS authors noted that the
95% confidence intervals (CIs) were quite wide (surgery
group, 9.9%; 95% CI, 6.2% to 13.6%) and overlapped with
the surgical results of both the European Carotid Surgery
Trial (7.0%; 95% CI, 5.8% to 8.1%) and the North
American Symptomatic Carotid Endarterectomy Trial
(6.5%; 95% CI, 5.2% to 7.8%). The authors concluded that
endovascular techniques were superior to surgery because
angioplasty provided equal protection against stroke and
death and avoided risks related to the neck incision and the
administration of general anesthesia.
Detractors and skeptics of carotid stent placement are
quick to point out the now infamous “stopped trial” by
Naylor et al. (3) in which five of seven carotid stent patients
suffered a stroke. These patients were treated by an inter-
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ventional radiologist with very limited carotid stent experi-
ence and were treated with inadequate antiplatelet therapy
by today’s standards.
Another trial that was stopped early by the sponsor, but
has not yet been published, is the Wallstent trial which
randomized 219 symptomatic patients and reported a 30-
day end point of any stroke or death in 12.1% of the stent
group and 4.5% in the surgery group (p  0.049) and a
1-year ipsilateral stroke rate of 3.6% in the surgery group
compared to 12.2% in the stent group (p 0.022) (4). Once
again, the stent-related complications clustered around the
inexperienced operators, while experienced operators expe-
rienced very few complications. There is a learning curve for
optimal carotid stent deployment as demonstrated by Rou-
bin et al. (5) who have the largest (to my knowledge)
published series of carotid stent placement. Clearly, poor
preparation and lack of experience regarding carotid stent
operators are linked with poor outcomes.
Carotid stenting is by far the most contentious area of
medicine today. This percutaneous alternative to carotid
surgery, predominantly performed by cardiologists, has
already become established in experienced centers as the
standard of care for patients at increased risk for surgery or
those with anatomically unfavorable lesions for carotid
endarterectomy (6). When large randomized trials in low
risk carotid endarterectomy candidates demonstrate equal or
better outcomes for stenting compared to surgery, then this
commonly performed vascular operation will become a
rarity. The impact of this potential change in clinical
practice has not been lost on our surgical colleagues who will
be forced to navigate between the Scylla of giving up this
patient volume to interventionalists and the Charybdis of
retraining in the field of endovascular intervention.
What does Brooks et al. (1) teach us? First, it shows that
in a relatively small sample of carefully selected, symptom-
atic patients with extracranial stenotic disease, and treated at
a single hospital, both surgery and stenting can be per-
formed safely and effectively with excellent results. Care
must be taken in translating these excellent results to
everyday practice as the risks and complications of both
carotid surgery and endovascular intervention are governed
by variable anatomic and clinical parameters (7). Comparing
outcomes between nonrandomized or unmatched groups
will lead to incorrect conclusions.
Brooks et al. (1) have positively demonstrated the up side
of carotid stenting, with very low procedural adverse events,
excellent patient acceptance and excellent late patency.
However, the authors’ claim “that CAS (carotid artery
stenting) has reached clinical equipoise with CEA (carotid
endarterectomy)” is not justified considering the limitations
of their study. However, with these promising data in hand,
balanced against the sobering knowledge that not every trial
of carotid stent placement has been able to achieve these
excellent results, the large multicenter randomized CREST
trial has begun, which will attempt to answer these pressing
clinical questions more definitively.
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